NCT00891917

Liq-NOL Efficacy in Pediatric Patients With Down Syndrome

Evaluation of Coenzyme q10 (Liq-nol®) Efficacy in Pediatric Patients With Down Syndrome

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Children's Hospital Medical Center, Cincinnati · Academic / Other
• Sex: All
• Age: 6 Years – 16 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to measure the effects of LiQ-NOL supplementation on language production using the Clinical Evaluation of Language Fundamentals test, language sampling using the mean length of utterance test, and speech articulation using the Goldman-Fristoe Test of Articulation.

Detailed description

This is a randomized, double-blind, placebo-controlled clinical study of CoQ efficacy in a crossover design. Patients will be screened, enrolled, and studied in the outpatient clinic of the Thomas Center for Down Syndrome at CCHMC. All patients will be randomly assigned to either a liquid product (LiQ-NOL®) and an identical placebo liquid. Study drug and placebo will be administered twice a day (morning and evening).

Conditions

• Down Syndrome

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Ubiquinol-10 Syrup	10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
DIETARY_SUPPLEMENT	syrup (placebo)	syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation

Timeline

• Start date: 2005-01-01
• Primary completion: 2012-11-01
• Completion: 2012-12-01
• First posted: 2009-05-01
• Last updated: 2020-09-09

Locations

1 site across 1 country: United States